Introduction
Angiosarcoma is an extremely rare malignant vessel tumor that comprises 1% of all soft tissue sarcomas (1) . It develops in subcutaneous tissue at many sites in the body, and a previous medical history of trauma, breast cancer, and/or radiotherapy are considered risk factors for the disease. Localized tumors are treated with surgical removal. However, for recurrent and unresectable conditions, there is limited evidence to support chemotherapy regimens. Here, we describe a patient with angiosarcoma that developed in the thoracic wall, which responded well to systemic chemotherapy composed of nanoparticle albumin-bound paclitaxel (nab-PTX).
Case report
An 81-year-old woman was referred to our hospital for an examination due to right chest pain. She had a history of right breast cancer and had undergone a mastectomy and adjuvant radiotherapy 10 years prior. Upon examination, a skin induration with tenderness was found on the right precordia. Computed tomography (CT) imaging of the chest demonstrated right pleural effusion and a lobular mass that involved the right anterior thoracic wall; this mass had partially extruded from the thoracic cavity into the subcutaneous tissue ( Figure 1A ). On enhanced CT images, the mass showed a contrast effect in the early stages of the arterial phase. The tumor was surgically excised. Pathological analyses of the tumor showed disarrayed growth of hyperchromatic and vasoformative mesenchymal tumor cells with abnormal mitosis ( Figure  2A ). Immunohistochemical analyses revealed that the cells were positive for CD31 ( Figure 2B ) and CD34 ( Figure 2C ), but negative for epithelial markers, S-100 ( Figure 2D ) and D2-40 ( Figure 2E ). Based on these findings, the diagnosis was confirmed as angiosarcoma. Five months after the operation, CT images showed 2 ) was delivered weekly. After 4 courses of chemotherapy, the masses in the pleura regressed remarkably ( Figure 1C ). The only adverse event was alopecia, no myelosuppression or neurotoxicity was observed. After a total of 14 courses of chemotherapy, multiple tumors reappeared, and the patient died at 18 months after the initial diagnosis. Autopsy was not allowed.
Discussion
Angiosarcoma is an uncommon malignant vessel tumor. Angiosarcoma can develop in the subcutaneous tissue in almost all parts of the body, but the most common sites are the head and neck, followed by the breast and liver (2) . Angiosarcoma of the pleura is extremely rare (3) . A history of breast cancer and radiation therapy are known risk factors for this disease (4, 5) , and both these factors were present in the current case study. There is limited evidence to support chemotherapy regimens for unresectable and recurrent angiosarcomas; however, a few reports have suggested that anthracyclines, ifosfamide, and taxanes are potential treatment options. A retrospective study showed that, when paclitaxel was used to treat unresectable angiosarcomas, progressionfree survival was achieved for 6.8 months for scalp angiosarcoma and 2.8 months for sites below the clavicle (6) . Nab-PTX is a novel, soluble, polyoxyethylated, castor oil-free, biologically interactive form of paclitaxel, which allows shorter infusion times and requires no premedication for hypersensitive reactions. Nab-PTX has been approved for breast cancer (7), non-small cell lung cancer (8) , and gastric cancer (9) in Japan. Moreover, in the future, it will be used in more patients as an alternative to PTX. In the current case, nab-PTX was delivered to an aged patient with recurrent angiosarcoma that had disseminated in the pleura. This treatment elicited a favorable response and few adverse events, though the tumor acquired resistance eventually. To our knowledge, the current case was the first to show that angiosarcoma significantly responded to nab-PTX. Our results suggested that weekly administration of nab-PTX may be an effective treatment option for recurrent angiosarcoma.
In conclusion, we described a case of angiosarcoma in the pleura, which showed a significant response to nab-PTX.
